Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 0.79 |
| ▸ | ESR1 | P03372 | 7/20 | 0.79 |
| ▸ | TP53 | P04637 | 4/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.75 |
| ▸ | PGR | P06401 | 3/20 | 0.74 |
| ▸ | AR | P10275 | 3/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.74 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13177178 | 1.00 | LMNA (1.00) | LMNACYP3A4KMT2AMEN1ALOX15 | |
| SCHEMBL12072310 | 1.00 | LMNA (1.00) | LMNACYP3A4KMT2AMEN1ALOX15 | |
| SCHEMBL8643294 | 1.00 | LMNA (1.00) | LMNACYP3A4KMT2AMEN1ALOX15 | |
| SCHEMBL8991456 | 1.00 | LMNA (1.00) | LMNACYP3A4KMT2AMEN1ALOX15 | |
| SCHEMBL147037 | 1.00 | LMNA (1.00) | LMNACYP3A4KMT2AMEN1ALOX15 | |
| SCHEMBL12186917 | 1.00 | LMNA (1.00) | LMNACYP3A4KMT2AMEN1ALOX15 | |
| SCHEMBL8495807 | 0.92 | LMNA (0.84) | LMNACYP3A4KMT2AMEN1ALOX15 | |
| SCHEMBL24103244 | 0.91 | LMNA (0.84) | LMNACYP3A4KMT2AMEN1ALOX15 | |
| SCHEMBL9273487 | 0.90 | LMNA (0.82) | LMNACYP3A4KMT2AMEN1ALOX15 | |
| SCHEMBL15292940 | 0.90 | LMNA (0.82) | LMNACYP3A4KMT2AMEN1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069217-A1 | Methods of prevention and treatment of ischemic damage | SIMPKINS JAMES W (US) | 2003-04-10 | — | — | US | disclosed |
| WO-2001010430-A9 | USE OF ESTROGEN COMPOUNDS FOR PREVENTION AND TREATMENT OF ISCHEMIC DAMAGE | UNIV FLORIDA (US) | 2002-07-11 | — | — | WO | disclosed |
| US-6350739-B1 | ADMINISTERING ENT-17-BETA-ESTRADIOL TO TREAT STROKE, TRAUMA, HEMORRHAGE, BRAIN DISORDERS AND MYOCARDIUM INFARCTION AND AFTER SURGERY | UNIVERSITY OF FLORIDA RESARCH FOUNDATION, INC. | 2002-02-26 | — | — | US | disclosed |
| EP-1143947-A2 | USE OF ESTROGEN COMPOUNDS FOR PREVENTION AND TREATMENT OF ISCHEMIC DAMAGE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001010430-A2 | USE OF ESTROGEN COMPOUNDS FOR PREVENTION AND TREATMENT OF ISCHEMIC DAMAGE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069217-A1 | Methods of prevention and treatment of ischemic damage | ESRRB, SHBG, ESR2 | LMNA 297/4885CYP3A4 2718/4885KMT2A 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.